Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

BACKGROUND: More than half of the patients selected based on KRAS mutation status fail to respond to the treatment with cetuximab in metastatic colorectal cancer (mCRC). We designed a study to identify additional biomarkers that could act as indicators for cetuximab treatment in mCRC. METHODS: We in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Principais autores: Kim, Seung Tae, Ahn, Tae Jin, Lee, Eunjin, Do, In-Gu, Lee, Su Jin, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kim, Suk Hyeong, Lee, Jeeyun, Kim, Hee Cheol
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4617450/
https://ncbi.nlm.nih.gov/pubmed/26486455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1759-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados